ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2015
Time for a change: addressing R&D and commercialization challenges for antibacterials.
Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Minimal Computational Framework for Systematic Identification of Antimicrobial Targets.bioRxiv : the preprint server for biology · 2026Article
- KlebPhaCol: a community-driven resource for Klebsiella research identified a novel phage family.Nucleic acids research · 2025Article
- Repurposing Etalocib suppresses multidrug-resistant Staphylococcus aureus by disrupting the bacterial membrane.BMC microbiology · 2025Article
- Measurement and prediction of small molecule retention by Gram-negative bacteria based on a large-scale LC/MS screen.Scientific reports · 2025Article
- Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria.npj antimicrobials and resistance · 2025Review
- An Overview of the Recent Advances in Antimicrobial Resistance.Microorganisms · 2024Review
- Editorial: Antimicrobial peptides and their druggability, bio-safety, stability, and resistance.Frontiers in microbiology · 2024Article
- The multivalency game ruling the biology of immunity.Biophysics reviews · 2023Review
- Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections.Journal of managed care & specialty pharmacy · 2023Article
- The Potential Role of Vaccines in Preventing Antimicrobial Resistance (AMR): An Update and Future Perspectives.Vaccines · 2023Review
- Antimicrobial Resistance and Its Drivers-A Review.Antibiotics (Basel, Switzerland) · 2022Review
- Natural products and their semi-synthetic derivatives against antimicrobial-resistant human pathogenic bacteria and fungi.Saudi journal of biological sciences · 2022Review
- The Optimal Permeation of Cyclic Boronates to Cross the Outer Membrane via the Porin Pathway.Antibiotics (Basel, Switzerland) · 2022Article
- Human Cryptic Host Defence Peptide GVF27 Exhibits Anti-Infective Properties against Biofilm Forming Members of thePharmaceuticals (Basel, Switzerland) · 2022Article
- Dendritic Hydrogels Induce Immune Modulation in Human Keratinocytes and Effectively Eradicate Bacterial Pathogens.Journal of the American Chemical Society · 2021Article
- Antimicrobial resistance: A challenge awaiting the post-COVID-19 era.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- Mining for novel antibiotics.Current opinion in microbiology · 2021Review
- Strategies for Discovering New Antibiotics from Bacteria in the Post-Genomic Era.Current microbiology · 2020Review
- Structural and functional comparison of Saccharomonospora azurea strains in terms of primycin producing ability.World journal of microbiology & biotechnology · 2020Article
- Antibacterial Discovery: 21st Century Challenges.Antibiotics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antibacterial therapeutic area has been described as the perfect storm. Resistance is increasing to the point that our hospitals encounter patients infected with untreatable pathogens, the overall industry pipeline is described as dry and most multinational pharmaceutical companies have withdrawn from the area. Major contributing factors to the declining antibacterial industry pipeline include scientific challenges, clinical/regulatory hurdles and low return on investment. This paper examines these challenges and proposes approaches to address them. There is a need for a broader scientific agenda to explore new approaches to discover and develop antibacterial agents. Additionally, ideas of how industry and academia could be better integrated will be presented. While promising progress in the regulatory environment has been made, more streamlined regulatory paths are still required and the solutions will lie in global harmonization and clearly defined guidance. Creating the right incentives for antibacterial research and development is critical and a new commercial model for antibacterial agents will be proposed. One key solution to help resolve both the problem of antimicrobial resistance (AMR) and lack of new drug development are rapid, cost-effective, accurate point of care diagnostics that will transform antibacterial prescribing and enable more cost-effective and efficient antibacterial clinical trials. The challenges of AMR are too great for any one group to resolve and success will require leadership and partnerships among academia, industry and governments globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.